Int J Stem Cells.  2021 Nov;14(4):351-365. 10.15283/ijsc20146.

Prospects for Manipulation of Mesenchymal Stem Cells in Tumor Therapy: Anti-Angiogenesis Property on the Spotlight

• Ghollasi M
• Ghasembaglou S
• Rahban D
• Korani M
• Motallebnezhad M
• Asadi M
• Zarredar H
• Salimi A

• KMID: 2522556
• DOI: http://doi.org/10.15283/ijsc20146

Abstract

The interactions between the tumor microenvironment and the tumor cells confers a condition that accelerate or decelerate the development of tumor. Of these cells, mesenchymal stem cells (MSCs) have the potential to modulate the tumor cells. MSCs have been established with double functions, whereby contribute to a tumorigenic or anti-tumor setting. Clinical studies have indicated the potential of MSCs to be used as tool in treating the human cancer cells. One of the advantageous features of MSCs that make them as a well-suited tool for cancer therapy is the natural tumor-trophic migration potential. A key specification of the tumor development has been stablished to be angiogenesis. As a result, manipulation of angiogenesis has become an attractive approach for cancer therapy. This review article will seek to clarify the anti-angiogenesis strategy in modulating the MSCs to treat the tumor cells.

Keyword

Mesenchymal stem cells; Angiogenesis; Cancer therapy; Tumor microenvironment

Figure

• 

  Fig. 1 The migration and homing of MSCs into the tumors. The inflammatory state conferred by the tumor microenvironment results in recruitment and homing of MSCs into tumor. After that, MSCs constitute the major cell type of the tumor microenvironment and play several functions.

Reference

References

1. Siegel RL, Miller KD, Jemal A. 2016; Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. DOI: 10.3322/caac.21332. PMID: 26742998.

2. Sawyers C. 2004; Targeted cancer therapy. Nature. 432:294–297. DOI: 10.1038/nature03095. PMID: 33195035. PMCID: PMC7655966.

3. Corsten MF, Shah K. 2008; Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol. 9:376–384. DOI: 10.1016/S1470-2045(08)70099-8. PMID: 18374291.

4. Teo AK, Vallier L. 2010; Emerging use of stem cells in regenerative medicine. Biochem J. 428:11–23. DOI: 10.1042/BJ20100102. PMID: 20423328.

5. Fathollahi A, Gabalou NB, Aslani S. 2018; Mesenchymal stem cell transplantation in systemic lupus erythematous, a mesenchymal stem cell disorder. Lupus. 27:1053–1064. DOI: 10.1177/0961203318768889. PMID: 29631514.

6. Zanganeh E, Soudi S, Zavaran Hosseini A, Khosrojerdi A. 2019; Repeated intravenous injection of adipose tissue derived mesenchymal stem cells enhances Th1 immune responses in Leishmania major-infected BALB/c mice. Immunol Lett. 216:97–105. DOI: 10.1016/j.imlet.2019.10.008. PMID: 31622634.

7. Khosrojerdi A, Soudi S, Hosseini AZ, Eshghi F, Shafiee A, Hashemi SM. 2021; Immunomodulatory and therapeutic effects of mesenchymal stem cells on organ dysfunction in sepsis. Shock. 55:423–440. DOI: 10.1097/SHK.0000000000001644. PMID: 32826813.

8. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. 2007; Angiogenesis in brain tumours. Nat Rev Neurosci. 8:610–622. DOI: 10.1038/nrn2175. PMID: 17643088.

9. Samant RS, Shevde LA. 2011; Recent advances in anti-angiogenic therapy of cancer. Oncotarget. 2:122–134. DOI: 10.18632/oncotarget.234. PMID: 21399234. PMCID: PMC3260813.

10. Javan MR, Khosrojerdi A, Moazzeni SM. 2019; New insights into implementation of mesenchymal stem cells in cancer therapy: prospects for anti-angiogenesis treatment. Front Oncol. 9:840. DOI: 10.3389/fonc.2019.00840. PMID: 31555593. PMCID: PMC6722482.

11. Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. 1966; Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 16:381–390. DOI: 10.1242/dev.16.3.381. PMID: 5336210.

12. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. 1968; Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplan-tation. 6:230–247. DOI: 10.1097/00007890-196803000-00009. PMID: 5654088.

13. Väänänen HK. 2005; Mesenchymal stem cells. Ann Med. 37:469–479. DOI: 10.1080/07853890500371957. PMID: 32807933. PMCID: PMC7704061.

14. Uccelli A, Moretta L, Pistoia V. 2008; Mesenchymal stem cells in health and disease. Nat Rev Immunol. 8:726–736. DOI: 10.1038/nri2395. PMID: 19172693.

15. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. 1999; Multilineage potential of adult human mesenchymal stem cells. Science. 284:143–147. DOI: 10.1126/science.284.5411.143. PMID: 10102814.

16. Le Blanc K, Pittenger M. 2005; Mesenchymal stem cells: progress toward promise. Cytotherapy. 7:36–45. DOI: 10.1016/S1465-3249(05)70787-8. PMID: 16040382.

17. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R. 2009; Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol. 183:993–1004. DOI: 10.4049/jimmunol.0900803. PMID: 19561093. PMCID: PMC3895445.

18. Nauta AJ, Fibbe WE. 2007; Immunomodulatory properties of mesenchymal stromal cells. Blood. 110:3499–3506. DOI: 10.1182/blood-2007-02-069716. PMID: 30516112.

19. Loebinger MR, Janes SM. 2010; Stem cells as vectors for antitumour therapy. Thorax. 65:362–369. DOI: 10.1136/thx.2009.128025. PMID: 20388765. PMCID: PMC3401681.

20. Mishra PJ, Mishra PJ, Glod JW, Banerjee D. 2009; Mesenchymal stem cells: flip side of the coin. Cancer Res. 69:1255–1258. DOI: 10.1158/0008-5472.CAN-08-3562. PMID: 19208837.

21. Anderson DJ, Gage FH, Weissman IL. 2001; Can stem cells cross lineage boundaries? Nat Med. 7:393–395. DOI: 10.1038/86439. PMID: 11283651.

22. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. 2002; Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 418:41–49. DOI: 10.1038/nature00870. PMID: 12077603.

23. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. 2001; Bone marrow cells regenerate infarcted myocardium. Nature. 410:701–705. DOI: 10.1038/35070587. PMID: 11287958.

24. Bentzon JF, Stenderup K, Hansen FD, Schroder HD, Abdallah BM, Jensen TG, Kassem M. 2005; Tissue distribution and engraftment of human mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene. Biochem Biophys Res Commun. 330:633–640. DOI: 10.1016/j.bbrc.2005.03.072. PMID: 15809044.

25. Mueller SM, Glowacki J. 2001; Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem. 82:583–590. DOI: 10.1002/jcb.1174. PMID: 11500936.

26. Stewart MC, Stewart AA. 2011; Mesenchymal stem cells: characteristics, sources, and mechanisms of action. Vet Clin North Am Equine Pract. 27:243–261. DOI: 10.1016/j.cveq.2011.06.004. PMID: 21872757.

27. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. 2006; Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 24:1294–1301. DOI: 10.1634/stemcells.2005-0342. PMID: 16410387.

28. Prindull G, Ben-Ishay Z, Ebell W, Bergholz M, Dirk T, Prindull B. 1987; CFU-F circulating in cord blood. Blut. 54:351–359. DOI: 10.1007/BF00626017. PMID: 3496136.

29. Erices A, Conget P, Minguell JJ. 2000; Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 109:235–242. DOI: 10.1046/j.1365-2141.2000.01986.x. PMID: 10848804.

30. Goodwin HS, Bicknese AR, Chien SN, Bogucki BD, Quinn CO, Wall DA. 2001; Multilineage differentiation activity by cells isolated from umbilical cord blood: expression of bone, fat, and neural markers. Biol Blood Marrow Transplant. 7:581–588. DOI: 10.1053/bbmt.2001.v7.pm11760145. PMID: 11760145.

31. Chang YJ, Shih DT, Tseng CP, Hsieh TB, Lee DC, Hwang SM. 2006; Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. Stem Cells. 24:679–685. DOI: 10.1634/stemcells.2004-0308. PMID: 16179428.

32. He Q, Wan C, Li G. 2007; Concise review: multipotent mesenchymal stromal cells in blood. Stem Cells. 25:69–77. DOI: 10.1634/stemcells.2006-0335. PMID: 16973831.

33. Hong HS, Lee J, Lee E, Kwon YS, Lee E, Ahn W, Jiang MH, Kim JC, Son Y. 2009; A new role of substance P as an injury-inducible messenger for mobilization of CD29(＋) stromal-like cells. Nat Med. 15:425–435. DOI: 10.1038/nm.1909.

34. Spaeth EL, Kidd S, Marini FC. 2012; Tracking inflammation-induced mobilization of mesenchymal stem cells. Methods Mol Biol. 904:173–190. DOI: 10.1007/978-1-61779-943-3_15. PMID: 22890932.

35. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. 2008; Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 15:730–738. DOI: 10.1038/gt.2008.39. PMID: 18401438.

36. Momin EN, Vela G, Zaidi HA, Quiñones-Hinojosa A. 2010; The oncogenic potential of mesenchymal stem cells in the treatment of cancer: directions for future research. Curr Immunol Rev. 6:137–148. DOI: 10.2174/157339510791111718. PMID: 20490366. PMCID: PMC2873198.

37. Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, Teng YD, Frenkel D, Li J, Sidman RL, Walsh CA, Snyder EY, Khoury SJ. 2004; Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A. 101:18117–18122. DOI: 10.1073/pnas.0408258102. PMID: 15608062. PMCID: PMC536055.

38. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A. 2006; Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells. 24:1254–1264. DOI: 10.1634/stemcells.2005-0271. PMID: 16410389.

39. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. 2005; Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65:3307–3318. DOI: 10.1158/0008-5472.CAN-04-1874. PMID: 15833864.

40. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, Baik GH, Shibata W, Diprete B, Betz KS, Friedman R, Varro A, Tycko B, Wang TC. 2011; Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 19:257–272. DOI: 10.1016/j.ccr.2011.01.020. PMID: 21316604. PMCID: PMC3060401.

41. Smith H, Whittall C, Weksler B, Middleton J. 2012; Chemokines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. Stem Cells Dev. 21:476–486. DOI: 10.1089/scd.2011.0025. PMID: 21513440.

42. Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, Stein I, Singh SP, Bedolla RB, Peled A, Troyer DA, Pikarsky E, Karin M, Farber JM. 2009; The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One. 4:e6695. DOI: 10.1371/journal.pone.0006695. PMID: 19690611. PMCID: PMC2723911.

43. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. 2004; Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10:942–949. DOI: 10.1038/nm1093. PMID: 15322536.

44. Jacobs JF, Idema AJ, Bol KF, Grotenhuis JA, de Vries IJ, Wesseling P, Adema GJ. 2010; Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol. 225:195–199. DOI: 10.1016/j.jneuroim.2010.05.020. PMID: 20537408.

45. De Becker A, Van Hummelen P, Bakkus M, Vande Broek I, De Wever J, De Waele M, Van Riet I. 2007; Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica. 92:440–449. DOI: 10.3324/haematol.10475. PMID: 17488654.

46. Qiu Y, Marquez-Curtis LA, Janowska-Wieczorek A. 2012; Mesen-chymal stromal cells derived from umbilical cord blood migrate in response to complement C1q. Cytotherapy. 14:285–295. DOI: 10.3109/14653249.2011.651532. PMID: 22264191.

47. François S, Bensidhoum M, Mouiseddine M, Mazurier C, Allenet B, Semont A, Frick J, Saché A, Bouchet S, Thierry D, Gourmelon P, Gorin NC, Chapel A. 2006; Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells. 24:1020–1029. DOI: 10.1634/stemcells.2005-0260.

48. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F. 2007; Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia. 21:304–310. DOI: 10.1038/sj.leu.2404489. PMID: 17170725.

49. Zhu Y, Sun Z, Han Q, Liao L, Wang J, Bian C, Li J, Yan X, Liu Y, Shao C, Zhao RC. 2009; Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia. 23:925–933. DOI: 10.1038/leu.2008.384. PMID: 19148141.

50. Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C, Li SF, Long D, Tan WD, Mao YQ, Zhang J, Li YP, Cheng JQ. 2008; The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther. 7:245–251. DOI: 10.4161/cbt.7.2.5296. PMID: 18059192.

51. Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD. 2008; Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett. 269:67–77. DOI: 10.1016/j.canlet.2008.04.032. PMID: 18571836.

52. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L, Zhang X. 2008; Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 18:500–507. DOI: 10.1038/cr.2008.40. PMID: 18364678.

53. Sun B, Roh KH, Park JR, Lee SR, Park SB, Jung JW, Kang SK, Lee YS, Kang KS. 2009; Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy. 11:289–298. DOI: 10.1080/14653240902807026. PMID: 19308770.

54. Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L, Bosco R, Ingrao S, Zavan B, Zauli G. 2010; Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One. 5:e11140. DOI: 10.1371/journal.pone.0011140. PMID: 20585401. PMCID: PMC2886845.

55. Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S, Bhattacharya J. 2009; Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood. 113:4197–4205. DOI: 10.1182/blood-2008-09-176198. PMID: 19036701. PMCID: PMC2676081.

56. Hanahan D, Weinberg RA. 2011; Hallmarks of cancer: the next generation. Cell. 144:646–674. DOI: 10.1016/j.cell.2011.02.013. PMID: 21376230.

57. Rhee KJ, Lee JI, Eom YW. 2015; Mesenchymal stem cell-mediated effects of tumor support or suppression. Int J Mol Sci. 16:30015–30033. DOI: 10.3390/ijms161226215. PMID: 26694366. PMCID: PMC4691158.

58. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. 2010; A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immuno-suppressive MSC2 phenotype. PLoS One. 5:e10088. DOI: 10.1371/journal.pone.0010088. PMID: 20436665. PMCID: PMC2859930.

59. Waterman RS, Henkle SL, Betancourt AM. 2012; Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One. 7:e45590. DOI: 10.1371/journal.pone.0045590. PMID: 23029122. PMCID: PMC3447765.

60. Houthuijzen JM, Daenen LG, Roodhart JM, Voest EE. 2012; The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br J Cancer. 106:1901–1906. DOI: 10.1038/bjc.2012.201. PMID: 22596239. PMCID: PMC3388567.

61. Poggi A, Giuliani M. 2016; Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment. Vaccines (Basel). 4:41. DOI: 10.3390/vaccines4040041. PMID: 27834810. PMCID: PMC5192361.

62. Li GC, Zhang HW, Zhao QC, Sun LI, Yang JJ, Hong L, Feng F, Cai L. 2016; Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor β1. Oncol Lett. 11:1089–1094. DOI: 10.3892/ol.2015.3997. PMID: 26893697. PMCID: PMC4733964.

63. Zhang T, Lee YW, Rui YF, Cheng TY, Jiang XH, Li G. 2013; Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther. 4:70. DOI: 10.1186/scrt221. PMID: 23763837. PMCID: PMC3707041.

64. Fregni G, Quinodoz M, Möller E, Vuille J, Galland S, Fusco C, Martin P, Letovanec I, Provero P, Rivolta C, Riggi N, Stamenkovic I. 2018; Reciprocal modulation of mesenchymal stem cells and tumor cells promotes lung cancer metastasis. EBioMedicine. 29:128–145. DOI: 10.1016/j.ebiom.2018.02.017. PMID: 29503225. PMCID: PMC5925622.

65. Ridge SM, Sullivan FJ, Glynn SA. 2017; Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 16:31. DOI: 10.1186/s12943-017-0597-8. PMID: 28148268. PMCID: PMC5286812.

66. Bergfeld SA, Blavier L, DeClerck YA. 2014; Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Mol Cancer Ther. 13:962–975. DOI: 10.1158/1535-7163.MCT-13-0400. PMID: 24502925. PMCID: PMC4000239.

67. Naderi EH, Skah S, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ruud E, Naderi S, Blomhoff HK. 2015; Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death. Mol Cancer. 14:14. DOI: 10.1186/s12943-014-0278-9. PMID: 25623255. PMCID: PMC4323193.

68. Bonuccelli G, Avnet S, Grisendi G, Salerno M, Granchi D, Dominici M, Kusuzaki K, Baldini N. 2014; Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget. 5:7575–7588. DOI: 10.18632/oncotarget.2243. PMID: 25277190. PMCID: PMC4202145.

69. Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL, Hung SC. 2013; Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene. 32:4343–4354. DOI: 10.1038/onc.2012.458. PMID: 23085755.

70. Lin G, Yang R, Banie L, Wang G, Ning H, Li LC, Lue TF, Lin CS. 2010; Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate. 70:1066–1073. DOI: 10.1002/pros.21140. PMID: 20232361. PMCID: PMC2877148.

71. Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, Itoh J, Umezawa A, Kijima H, Fukuda S, Saijo Y. 2011; Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med. 17:579–587. DOI: 10.2119/molmed.2010.00157. PMID: 21424106. PMCID: PMC3146617.

72. Li Z. 2013; CD133: a stem cell biomarker and beyond. Exp Hematol Oncol. 2:17. DOI: 10.1186/2162-3619-2-17. PMID: 23815814. PMCID: PMC3701589.

73. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS. 2011; Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71:614–624. DOI: 10.1158/0008-5472.CAN-10-0538. PMID: 21224357. PMCID: PMC3100554.

74. Nishimura K, Semba S, Aoyagi K, Sasaki H, Yokozaki H. 2012; Mesenchymal stem cells provide an advantageous tumor microenvironment for the restoration of cancer stem cells. Pathobiology. 79:290–306. DOI: 10.1159/000337296. PMID: 22688186.

75. Corcoran KE, Trzaska KA, Fernandes H, Bryan M, Taborga M, Srinivas V, Packman K, Patel PS, Rameshwar P. 2008; Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One. 3:e2563. DOI: 10.1371/journal.pone.0002563. PMID: 18575622. PMCID: PMC2430536.

76. Xu WT, Bian ZY, Fan QM, Li G, Tang TT. 2009; Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 281:32–41. DOI: 10.1016/j.canlet.2009.02.022. PMID: 19342158.

77. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. 2007; Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 449:557–563. DOI: 10.1038/nature06188. PMID: 17914389.

78. Tsukamoto S, Honoki K, Fujii H, Tohma Y, Kido A, Mori T, Tsujiuchi T, Tanaka Y. 2012; Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Int J Oncol. 40:163–169. DOI: 10.3892/ijo.2011.1220. PMID: 21971610.

79. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noël D, Jorgensen C. 2003; Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 102:3837–3844. DOI: 10.1182/blood-2003-04-1193. PMID: 12881305.

80. Lee HY, Hong IS. 2017; Double-edged sword of mesenchymal stem cells: cancer-promoting versus therapeutic potential. Cancer Sci. 108:1939–1946. DOI: 10.1111/cas.13334. PMID: 28756624. PMCID: PMC5623746.

81. Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS, Burow ME. 2010; Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer. 9:295. DOI: 10.1186/1476-4598-9-295. PMID: 21087507. PMCID: PMC2998478.

82. Halpern JL, Kilbarger A, Lynch CC. 2011; Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett. 308:91–99. DOI: 10.1016/j.canlet.2011.04.018. PMID: 21601983. PMCID: PMC3311035.

83. Tsai KS, Yang SH, Lei YP, Tsai CC, Chen HW, Hsu CY, Chen LL, Wang HW, Miller SA, Chiou SH, Hung MC, Hung SC. 2011; Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology. 141:1046–1056. DOI: 10.1053/j.gastro.2011.05.045. PMID: 21699785.

84. Melzer C, Yang Y, Hass R. 2016; Interaction of MSC with tumor cells. Cell Commun Signal. 14:20. DOI: 10.1186/s12964-016-0143-0. PMID: 27608835. PMCID: PMC5016940.

85. Norozi F, Ahmadzadeh A, Shahrabi S, Vosoughi T, Saki N. 2016; Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells. Tumour Biol. 37:11679–11689. DOI: 10.1007/s13277-016-5187-7. PMID: 27440203.

86. Raposo G, Stoorvogel W. 2013; Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 200:373–383. DOI: 10.1083/jcb.201211138. PMID: 23420871. PMCID: PMC3575529.

87. Braicu C, Tomuleasa C, Monroig P, Cucuianu A, Berindan-Neagoe I, Calin GA. 2015; Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ. 22:34–45. DOI: 10.1038/cdd.2014.130. PMID: 25236394. PMCID: PMC4262777.

88. Zhang L, Hao C, Yao S, Tang R, Guo W, Cong H, Li J, Bao L, Wang D, Li Y, Yu X, Duan S, Yao W. 2018; Exosomal miRNA profiling to identify nanoparticle phagocytic mechanisms. Small. 14:e1704008. DOI: 10.1002/smll.201704008. PMID: 29516679.

89. Zarredar H, Ansarin K, Baradaran B, Shekari N, Eyvazi S, Safari F, Farajnia S. 2018; Critical microRNAs in lung cancer: recent advances and potential applications. Anticancer Agents Med Chem. 18:1991–2005. DOI: 10.2174/1871520618666180808125459. PMID: 30088452.

90. Zafari V, Shanehbandi D, Bornehdeli S, Sadeghzadeh M, Zarredar H, Asadi M, Sharifi A. 2021; MicroRNA profiling in non-small cell lung cancer and its implications for the disease pathogenesis. Middle East J Cancer. 12:79–85.

91. Neviani P, Fabbri M. 2015; Exosomic microRNAs in the tumor microenvironment. Front Med (Lausanne). 2:47. DOI: 10.3389/fmed.2015.00047. PMID: 26258125. PMCID: PMC4510410.

92. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, Ratajczak MZ. 2006; Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 20:847–856. DOI: 10.1038/sj.leu.2404132. PMID: 16453000.

93. Burrello J, Monticone S, Gai C, Gomez Y, Kholia S, Camussi G. 2016; Stem cell-derived extracellular vesicles and immune-modulation. Front Cell Dev Biol. 4:83. DOI: 10.3389/fcell.2016.00083. PMID: 27597941. PMCID: PMC4992732.

94. Pinto A, Marangon I, Méreaux J, Nicolás-Boluda A, Lavieu G, Wilhelm C, Sarda-Mantel L, Silva AKA, Pocard M, Gazeau F. 2021; Immune reprogramming precision photodynamic therapy of peritoneal metastasis by scalable stem-cell-derived extracellular vesicles. ACS Nano. 15:3251–3263. DOI: 10.1021/acsnano.0c09938. PMID: 33481565.

95. Gowen A, Shahjin F, Chand S, Odegaard KE, Yelamanchili SV. 2020; Mesenchymal stem cell-derived extracellular vesicles: challenges in clinical applications. Front Cell Dev Biol. 8:149. DOI: 10.3389/fcell.2020.00149. PMID: 32226787. PMCID: PMC7080981.

96. Zhou Y, Xu H, Xu W, Wang B, Wu H, Tao Y, Zhang B, Wang M, Mao F, Yan Y, Gao S, Gu H, Zhu W, Qian H. 2013; Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther. 4:34. DOI: 10.1186/scrt194. PMID: 23618405. PMCID: PMC3707035.

97. Zhu W, Huang L, Li Y, Zhang X, Gu J, Yan Y, Xu X, Wang M, Qian H, Xu W. 2012; Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 315:28–37. DOI: 10.1016/j.canlet.2011.10.002. PMID: 22055459.

98. Bruno S, Collino F, Deregibus MC, Grange C, Tetta C, Camussi G. 2013; Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev. 22:758–771. DOI: 10.1089/scd.2012.0304. PMID: 23034046.

99. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, Kim YG, Jang JY, Kim CW. 2013; Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One. 8:e84256. DOI: 10.1371/journal.pone.0084256. PMID: 24391924. PMCID: PMC3877259.

100. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y. 2006; MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One. 1:e116. DOI: 10.1371/journal.pone.0000116. PMID: 17205120. PMCID: PMC1762435.

101. Karimi L, Zeinali T, Hosseinahli N, Mansoori B, Mohammadi A, Yousefi M, Asadi M, Sadreddini S, Baradaran B, Shanehbandi D. 2019; miRNA-143 replacement therapy harnesses the proliferation and migration of colorectal cancer cells in vitro. J Cell Physiol. 234:21359–21368. DOI: 10.1002/jcp.28745. PMID: 31032951.

102. Shimbo K, Miyaki S, Ishitobi H, Kato Y, Kubo T, Shimose S, Ochi M. 2014; Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem Biophys Res Commun. 445:381–387. DOI: 10.1016/j.bbrc.2014.02.007. PMID: 24525123.

103. Maestroni GJ, Hertens E, Galli P. 1999; Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci. 55:663–667. DOI: 10.1007/s000180050322. PMID: 10357234.

104. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y, Hamada H. 2004; Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11:1155–1164. DOI: 10.1038/sj.gt.3302276. PMID: 15141157.

105. Qiao C, Xu W, Zhu W, Hu J, Qian H, Yin Q, Jiang R, Yan Y, Mao F, Yang H, Wang X, Chen Y. 2008; Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int. 32:8–15. DOI: 10.1016/j.cellbi.2007.08.002. PMID: 17904875.

106. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T. 2006; Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med. 203:1235–1247. DOI: 10.1084/jem.20051921. PMCID: PMC2121206.

107. Gondi CS, Veeravalli KK, Gorantla B, Dinh DH, Fassett D, Klopfenstein JD, Gujrati M, Rao JS. 2010; Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo. Neuro Oncol. 12:453–465. DOI: 10.1093/neuonc/nop049. PMID: 20406896. PMCID: PMC2940623.

108. Dasari VR, Velpula KK, Kaur K, Fassett D, Klopfenstein JD, Dinh DH, Gujrati M, Rao JS. 2010; Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP). PLoS One. 5:e11813. DOI: 10.1371/journal.pone.0011813. PMID: 20676365. PMCID: PMC2911373.

109. Akimoto K, Kimura K, Nagano M, Takano S, To'a Salazar G, Yamashita T, Ohneda O. 2013; Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev. 22:1370–1386. DOI: 10.1089/scd.2012.0486. PMID: 23231075. PMCID: PMC3696928.

110. Wilting J, Christ B. 1996; Embryonic angiogenesis: a review. Naturwissenschaften. 83:153–164. DOI: 10.1007/BF01143056. PMID: 8643122.

111. Risau W, Flamme I. 1995; Vasculogenesis. Annu Rev Cell Dev Biol. 11:73–91. DOI: 10.1146/annurev.cb.11.110195.000445. PMID: 8689573.

112. Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H, Eyvazi S. 2019; Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol. 234:2134–2142. DOI: 10.1002/jcp.27581. PMID: 30317611.

113. Folkman J. 1971; Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. DOI: 10.1056/NEJM197111182852108. PMID: 4938153.

114. Ribatti D. 2004; The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med. 8:294–300. DOI: 10.1111/j.1582-4934.2004.tb00319.x. PMID: 15491505. PMCID: PMC6740146.

115. Ferrara N, Henzel WJ. 1989; Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 161:851–858. DOI: 10.1016/0006-291X(89)92678-8. PMID: 22925671.

116. Khoury CC, Ziyadeh FN. 2011; Angiogenic factors. Contrib Nephrol. 170:83–92. DOI: 10.1159/000324950. PMID: 21659761.

117. Taraboletti G, Rusnati M, Ragona L, Colombo G. 2010; Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget. 1:662–673. DOI: 10.18632/oncotarget.200. PMID: 21317461. PMCID: PMC3248139.

118. Algire GH, Chalkley HW, Legallais FY, Park HD. 1945; Vasculae reactions of normal and malignant tissues in vivo. I. vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst. 6:73–85. DOI: 10.1093/jnci/6.1.73.

119. Zarredar H, Ansarin K, Baradaran B, Ahdi Khosroshahi S, Farajnia S. 2018; Potential molecular targets in the treatment of lung cancer using siRNA technology. Cancer Invest. 36:37–58. DOI: 10.1080/07357907.2017.1416393. PMID: 29336624.

120. Ferrara N, Gerber HP, LeCouter J. 2003; The biology of VEGF and its receptors. Nat Med. 9:669–676. DOI: 10.1038/nm0603-669. PMID: 12778165.

121. Wang GL, Semenza GL. 1995; Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 270:1230–1237. DOI: 10.1074/jbc.270.3.1230. PMID: 7836384.

122. Brahimi-Horn C, Pouysségur J. 2006; The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer. 93:E73–E80. DOI: 10.1016/j.bcp.2006.10.013. PMID: 16935775.

123. Ellis LM, Hicklin DJ. 2008; VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 8:579–591. DOI: 10.1038/nrc2403. PMID: 18596824.

124. Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski B, Sihto H, Laakkonen P, Heikkilä P, Joensuu H, Alitalo K. 2008; VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell. 13:554–556. DOI: 10.1016/j.ccr.2008.04.022. PMID: 18538738.

125. Zarredar H, Pashapour S, Ansarin K, Khalili M, Baghban R, Farajnia S. 2019; Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro. J Cell Physiol. 234:1560–1566. DOI: 10.1002/jcp.27021. PMID: 30132854.

126. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. 1993; Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841–844. DOI: 10.1038/362841a0. PMID: 7683111.

127. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. 1997; Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:4593–4599. PMID: 9377574.

128. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. 2004; Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. DOI: 10.1056/NEJMoa032691. PMID: 15175435.

129. Asadi M, Shanehbandi D, Zarintan A, Pedram N, Baradaran B, Zafari V, Shirmohamadi M, Hashemzadeh S. 2017; TP53 gene Pro72Arg (rs1042522) single nucleotide polymorphism as not a risk factor for colorectal cancer in the Iranian Azari Population. Asian Pac J Cancer Prev. 18:3423–3427.

130. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. 2006; Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. DOI: 10.1056/NEJMoa061884. PMID: 17167137.

131. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. 2007; Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. DOI: 10.1056/NEJMoa072113. PMID: 18160686.

132. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. 2002; VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 99:11393–11398. DOI: 10.1073/pnas.172398299. PMID: 12177445. PMCID: PMC123267.

133. Ellis LM, Hicklin DJ. 2008; Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 14:6371–6375. DOI: 10.1158/1078-0432.CCR-07-5287. PMID: 18927275.

134. Kerbel RS. 2008; Tumor angiogenesis. N Engl J Med. 358:2039–2049. DOI: 10.1056/NEJMra0706596. PMID: 4938153.

135. Jiang F, Albert DH, Luo Y, Tapang P, Zhang K, Davidsen SK, Fox GB, Lesniewski R, McKeegan EM. 2011; ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models. J Pharmacol Exp Ther. 338:134–142. DOI: 10.1124/jpet.110.178061. PMID: 21505059.

136. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. 2011; Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 6:1418–1425. DOI: 10.1097/JTO.0b013e318220c93e. PMID: 21597387.

137. You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM. 2011; VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71:4758–4768. DOI: 10.1158/0008-5472.CAN-10-2527. PMID: 21613405. PMCID: PMC3138890.

138. Ho TH, Jonasch E. 2011; Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncol. 7:1247–1253. DOI: 10.2217/fon.11.107. PMID: 22044199.

139. Eskens FA, de Jonge MJ, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J. 2011; Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res. 17:7156–7163. DOI: 10.1158/1078-0432.CCR-11-0411. PMID: 21976547.

140. Langmuir PB, Yver A. 2012; Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther. 91:71–80. DOI: 10.1038/clpt.2011.272. PMID: 22158569.

141. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. 2003; SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 101:3597–3605. DOI: 10.1182/blood-2002-07-2307. PMID: 12531805.

142. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY. 2009; Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 27:3126–3132. DOI: 10.1200/JCO.2008.21.3223. PMID: 19451427.

143. Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O, Brendel E, Schwartz B, Ludwig M, Flashar C, Voigtmann R, Scheulen ME, Seeber S, Strumberg D. 2006; Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol. 17:866–873. DOI: 10.1093/annonc/mdl017. PMID: 16500908.

144. Jain RK. 2005; Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58–62. DOI: 10.1126/science.1104819. PMID: 15637262.

145. Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC. 2006; Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery. Nat Clin Pract Oncol. 3:682–692. DOI: 10.1038/ncponc0663. PMID: 17139319.

146. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E. 2008; Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer. 99:2006–2012. DOI: 10.1038/sj.bjc.6604808. PMID: 19078952. PMCID: PMC2607218.

147. Ghaedi M, Soleimani M, Taghvaie NM, Sheikhfatollahi M, Azadmanesh K, Lotfi AS, Wu J. 2011; Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. J Gene Med. 13:171–180. DOI: 10.1002/jgm.1552. PMID: 21449040.

148. Toi M, Hoshina S, Takayanagi T, Tominaga T. 1994; Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res. 85:1045–1049. DOI: 10.1111/j.1349-7006.1994.tb02904.x. PMID: 7525523. PMCID: PMC5919354.

149. Folkman J, Watson K, Ingber D, Hanahan D. 1989; Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:58–61. DOI: 10.1038/339058a0. PMID: 2469964.

150. Zheng L, Zhang D, Chen X, Yang L, Wei Y, Zhao X. 2012; Antitumor activities of human placenta-derived mesenchymal stem cells expressing endostatin on ovarian cancer. PLoS One. 7:e39119. DOI: 10.1371/journal.pone.0039119. PMID: 22911684. PMCID: PMC3404061.

151. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. 2007; AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 11:83–95. DOI: 10.1016/j.ccr.2006.11.021. PMID: 17222792. PMCID: PMC2748664.

152. Kadambi A, Mouta Carreira C, Yun CO, Padera TP, Dolmans DE, Carmeliet P, Fukumura D, Jain RK. 2001; Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61:2404–2408. PMID: 11289105.

153. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. 2004; Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64:3731–3736. DOI: 10.1158/0008-5472.CAN-04-0074. PMID: 15172975.

154. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, Scheding S, Bengzon J. 2009; Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther. 17:183–190. DOI: 10.1038/mt.2008.229. PMID: 18985030. PMCID: PMC2834971.

155. Mirzaei H, Salehi H, Oskuee RK, Mohammadpour A, Mirzaei HR, Sharifi MR, Salarinia R, Darani HY, Mokhtari M, Masoudifar A, Sahebkar A, Salehi R, Jaafari MR. 2018; The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model. Cancer Lett. 419:30–39. DOI: 10.1016/j.canlet.2018.01.029. PMID: 29331419.

156. Hyder SM, Stancel GM. 1999; Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol. 13:806–811. DOI: 10.1210/mend.13.6.0308. PMID: 10379879.

157. Zygmunt M, Herr F, Münstedt K, Lang U, Liang OD. 2003; Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol. 110 Suppl 1:S10–S18. DOI: 10.1016/S0301-2115(03)00168-4. PMID: 12965086.

158. Jensen EV, Jordan VC. 2003; The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 9:1980–1989. PMID: 12796359.

159. Horwitz KB. 1988; The central role of progesterone receptors and progestational agents in the management and treatment of breast cancer. Semin Oncol. 15(2 Suppl 1):14–19. PMID: 3285481.

160. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA. 1997; Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138:863–870. DOI: 10.1210/endo.138.3.4979. PMID: 9048584.

161. Chang WY, Prins GS. 1999; Estrogen receptor-beta: implications for the prostate gland. Prostate. 40:115–124. DOI: 10.1002/(SICI)1097-0045(19990701)40:2<115::AID-PROS7>3.0.CO;2-3. PMID: 10386472.

162. Makar AP. 2000; Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer. 7:85–93. DOI: 10.1677/erc.0.0070085. PMID: 10903526.

163. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Writing Group for the Women's Health Initiative Investigators. 2002; Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 288:321–333. DOI: 10.1001/jama.288.3.321. PMID: 12117397.

164. Vázquez F, Rodríguez-Manzaneque JC, Lydon JP, Edwards DP, O'Malley BW, Iruela-Arispe ML. 1999; Progesterone regulates proliferation of endothelial cells. J Biol Chem. 274:2185–2192. DOI: 10.1074/jbc.274.4.2185. PMID: 9890981.

165. Iruela-Arispe ML, Rodriguez-Manzaneque JC, Abu-Jawdeh G. 1999; Endometrial endothelial cells express estrogen and progesterone receptors and exhibit a tissue specific response to angiogenic growth factors. Microcirculation. 6:127–140. DOI: 10.1080/713773947. PMID: 10466115.

166. Reynolds LP, Redmer DA. 1999; Growth and development of the corpus luteum. J Reprod Fertil Suppl. 54:181–191. PMID: 10692854.

167. Chuderland D, Ben-Ami I, Kaplan-Kraicer R, Grossman H, Komsky A, Satchi-Fainaro R, Eldar-Boock A, Ron-El R, Shalgi R. 2013; Hormonal regulation of pigment epithelium-derived factor (PEDF) in granulosa cells. Mol Hum Reprod. 19:72–81. DOI: 10.1093/molehr/gas046. PMID: 23075882.

168. Shah K. 2012; Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev. 64:739–748. DOI: 10.1016/j.addr.2011.06.010. PMID: 21740940. PMCID: PMC3395998.

169. Levy O, Zhao W, Mortensen LJ, Leblanc S, Tsang K, Fu M, Phillips JA, Sagar V, Anandakumaran P, Ngai J, Cui CH, Eimon P, Angel M, Lin CP, Yanik MF, Karp JM. 2013; mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood. 122:e23–e32. DOI: 10.1182/blood-2013-04-495119. PMID: 23980067. PMCID: PMC3790516.

170. Vartanian A, Karshieva S, Dombrovsky V, Belyavsky A. 2016; Melanoma educates mesenchymal stromal cells towards vasculogenic mimicry. Oncol Lett. 11:4264–4268. DOI: 10.3892/ol.2016.4523. PMID: 27313776. PMCID: PMC4888129.

171. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ. 2012; Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 7:e47559. DOI: 10.1371/journal.pone.0047559. PMID: 23133515. PMCID: PMC3485008.

172. Hong S, Tan M, Wang S, Luo S, Chen Y, Zhang L. 2015; Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 141:909–921. DOI: 10.1007/s00432-014-1862-5. PMID: 25373315.

173. Li X, Zhu S, Hong C, Cai H. 2016; Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials. Curr Med Res Opin. 32:555–562. DOI: 10.1185/03007995.2015.1131152. PMID: 26652645.

174. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. 2011; Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest. 121:1313–1328. DOI: 10.1172/JCI42405. PMID: 21436589. PMCID: PMC3070607.

175. Semenza GL. 2014; Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 9:47–71. DOI: 10.1146/annurev-pathol-012513-104720. PMID: 23937437.

176. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. 2009; Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220–231. DOI: 10.1016/j.ccr.2009.01.027. PMID: 19249680. PMCID: PMC2874829.